Recombinant rabies virus vaccine with molecular adjuvant induces strong immune responses and protection in mice

This study aimed to improve the effectiveness of the rabies vaccine to help alleviate and eliminate the rabies epidemic.

Straumann Group 2024 half-year results webcast – Biotech Investments

Straumann Holding AG / Key word(s): Half Year Results/Sales Result Invitation: Straumann Group 2024 half-year results webcast 05.08.2024 / 13:30 CET/CEST Date: Wednesday, August 14,

August 6, 2024

Solascure and U.S. Army Institute of Surgical Research collaborate for combat wound care

SOLASCURE Ltd (“SolasCure”), a biotechnology company developing a novel treatment to transform chronic wound care and the U.S. Army Institute of Surgical Research (“USAISR”), today

November 6, 2024

Study challenges migraine-Parkinson’s connection

Contrary to previous research, a new study of female participants finds no link between migraine and the risk of developing Parkinson’s disease. The study was

August 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.